Several patients have been harmed by Tasigna, a drug that helps to treat Atherosclerosis. However, this drug has been found to have a lot of side effects, including an increased risk of a heart attack or stroke. The lawsuit claims that the drug can cause patients to suffer serious injuries and even death.

Atherosclerosis

Several lawsuits have been filed against Tasigna. They allege that the drug caused severe and irreversible atherosclerosis. These lawsuits also claim that Novartis did not warn consumers and healthcare professionals about the risk of atherosclerosis.

Tasigna is a chemotherapy drug for the treatment of chronic myeloid leukemia. It is prescribed to adults with Philadelphia chromosome-positive chronic myeloid leukemia who have not responded well to previous therapies.

In 2013, the Health Canada informed Canadians of the risk of Tasigna. This information was added to the Product Monograph and Consumer Information Leaflet. However, there was no prominent warning on the label. It is suspected that Novartis knew about the risks of Tasigna for accelerated atherosclerosis for years, but did not inform the public.

Multi-district litigation

Earlier this year, the U.S. Department of Justice filed charges against Novartis, a pharmaceutical company, for their failure to warn about the risk of Tasigna, which is used to treat chronic myeloid leukemia. Tasigna is a tyrosine kinase inhibitor, which works by slowing the accelerated growth of abnormal cancer cells. It is used for adults who are intolerant of prior therapies, and it is prescribed by physicians.

Novartis failed to adequately warn of Tasigna’s serious side effects, such as atherosclerosis and irreversible atherosclerosis. Atherosclerosis is a disease that causes plaque to build up in the blood vessels, causing them to harden and narrow. This can lead to a stroke or heart attack.

Plaintiffs’ injuries

Several lawsuits have been filed against Novartis for failing to warn the public of the risks associated with Tasigna. Tasigna is a drug used to treat chronic myeloid leukemia. It belongs to a class of drugs known as kinase inhibitors. Some side effects of Tasigna include muscle weakness, joint pain, headache, nausea and diarrhea.

In 2013, Health Canada alerted Canadians to the possible connection between Tasigna and atherosclerosis. Atherosclerosis is a type of cardiovascular disease that slowly develops over time. It affects the arteries in the body, which narrow and harden. It can lead to several complications, including heart attacks and amputations.

A Tasigna lawsuit was filed in California by the wife of a Tasigna user. The lawsuit alleges that Tasigna caused Dainis Lauris’s death in 2014. It is also alleged that Tasigna caused her to suffer severe atherosclerosis. The lawsuit claims that Novartis failed to warn patients and doctors of Tasigna’s potential risks.

Cost of the drug

Several doctors and researchers have been arguing that drug prices are immoral and astronomical. According to the FDA, the cost of a drug can range from as little as a few dollars to thousands of dollars per month.

Tasigna is a brand name drug manufactured by Novartis. It is a drug designed to treat patients with Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase.

While Tasigna is not the cheapest drug on the block, it does have a few notable features. One is its longer patent life, which means you will be able to get a new bottle as opposed to a used one. Another is its ability to target proteins found in cancer cells. Its ability to attack cancer cells has been well documented.

At-risk patients

Several lawsuits have been filed against Novartis over its Tasigna drug. They allege that Novartis failed to warn patients and the public of the risks associated with the drug.

Tasigna is a drug that was developed to treat chronic myeloid leukemia. Chronic myeloid leukemia is a cancer that begins in the bone marrow and enters the bloodstream. It is an uncommon type of leukemia that affects approximately 15% of adult patients.

Tasigna is prescribed to treat chronic myeloid leukemia, but the drug was also developed to slow the growth of cancer. The drug has been linked to atherosclerosis, or plaque buildup in arteries. This causes them to narrow and harden, causing serious complications.

Trial set for Oct. 29, 2018

Hundreds of supporters of youth plaintiffs crowded the Wayne Morse Federal Courthouse in Eugene, Oregon for the oral arguments in the landmark climate change case, Juliana v. U. The plaintiffs, who are primarily teenagers, are asking the federal government to take action on climate change in order to protect their future.

The plaintiffs are asking the government to make a scientifically-based decision to reduce atmospheric carbon dioxide concentrations to 350 parts per million (ppm) by the year 2100. The case is supported by Our Children’s Trust, a non-profit group.

The Trump administration has used dramatic tactics to try to keep science and facts out of the courtroom. These include a petition for a writ of mandamus and a motion for summary judgment.